| [1]Li Y, Shi H, Wang WM, et al.Prevalence,awareness,and treatment of anemia in Chinese patients with nondialysis chronic kidney disease: First multicenter,cross-sectional study[J].Medicine (Baltimore), 2016, 95(24):e3872-
[2]Zuo L, Wang M, Hou F, et al.Anemia management in the China dialysis outcomes and practice patterns study[J].Blood Purif, 2016, 42(1):33-43
[3]Portolés J, Gorriz JL, Rubio E, et al.The development of anemia is associated to poor prognosis in NKF/KDOQI stage 3 chronic kidney disease[J]. BMC nephrology, 2013, 14: 2-2.
[4]Sato Y, Fujimoto S, Konta T, et al.Anemia as a risk factor for all-cause mortality: Obscure synergic effect of chronic kidney disease[J].Clin Exp Nephrol, 2018, 22(2):388-394
[5]Spinowitz B, Pecoits-Filho R, Winkelmayer WC, et al.Economic and quality of life burden of anemia on patients with CKD on dialysis: A systematic review[J].Journal of medical economics, 2019, 22(6):593-604
[6]Pergola PE, Pecoits-Filho R, Winkelmayer WC, et al.Economic burden and health-related quality of life associated with current treatments for anaemia in patients with CKD not on dialysis: A systematic review[J].PharmacoEconomics - open, 2019, 3(4):463-478
[7]Cody JD, Hodson EM.Recombinant human erythropoietin versus placebo or no treatment for the anaemia of chronic kidney disease in people not requiring dialysis[J]. The Cochrane database of systematic reviews, 2016, (1): CD003266.
[8]Stephens JM, Emerson LC, Spry LA, et al.Time savings of weekly versus three-times-per-week administration of erythropoiesis stimulating agents in united states dialysis patients[J].Current medical research and opinion, 2016, 32(2):313-320
[9]Wilhelm-Leen ER, Winkelmayer WC.Mortality risk of darbepoetin alfa versus epoetin alfa in patients with CKD: Systematic review and meta-analysis[J].Am J Kidney Dis, 2015, 66(1):69-74
[10]Martínez-Castelao A, Cases A, Coll E, et al.C.ER.A. Administered once monthly corrects and maintains stable hemoglobin levels in chronic kidney disease patients not on dialysis: The observational study MICENAS II[J].Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia, 2015, 35(1):80-86
[11]Fischbach M, Wühl E, Reigner SCM, et al.Efficacy and long-term safety of CE.R.A. Maintenance in pediatric hemodialysis patients with anemia of CKD[J].Clin J Am Soc Nephrol, 2018, 13(1):81-90
[12]Kuwahara M, Arai Y, Takehara E, et al.Early response to erythropoiesis-stimulating agents in non-dialysis chronic kidney disease patients[J].Clin Exp Nephrol, 2016, 20(4):585-594
[13]Saglimbene VM, Palmer SC, Ruospo M, et al.Continuous erythropoiesis receptor activator (CERA) for the anaemia of chronic kidney disease[J].The Cochrane database of systematic reviews, 2017, 8(8):C-D009904
[14]Locatelli F, Hannedouche T, Fishbane S, et al.Cardiovascular safety and all-cause mortality of methoxy polyethylene glycol-epoetin beta and other erythropoiesis-stimulating agents in anemia of CKD: A randomized noninferiority trial[J].Clin J Am Soc Nephrol, 2019, 14(12):1701-1710
[15]Sakaguchi Y, Hamano T, Wada A, et al.Types of erythropoietin-stimulating agents and mortality among patients undergoing hemodialysis[J].J Am Soc Nephrol, 2019, 30(6):1037-1048
[16]Kotarek J, Stuart C, De Paoli SH, et al.Subvisible particle content,formulation,and dose of an erythropoietin peptide mimetic product are associated with severe adverse postmarketing events[J].Journal of pharmaceutical sciences, 2016, 105(3):1023-1027
[17]Kortman GAM, Reijnders D, Swinkels DW.Oral iron supplementation: Potential implications for the gut microbiome and metabolome in patients with CKD[J]. Hemodialysis international International Symposium on Home Hemodialysis, 2017, 21 Suppl 1: S28-S36.
[18]Red Blood Cell Diseases Group, Chinese Society of Hematology Chinese Medical Association.Chinese expert consensus on the application of intravenous iron (2019)][J].Zhonghua Xue Ye Xue Za Zhi, 2019, 40(5):358-362
[19]O' Lone EL, Hodson EM, Nistor I, et al.Parenteral versus oral iron therapy for adults and children with chronic kidney disease[J]. The Cochrane database of systematic reviews, 2019, 2: CD007857.
[20]Macdougall IC, Bock AH, Carrera F, et al.FIND-CKD: A randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia[J].Nephrol Dial Transplant, 2014, 29(11):2075-2084
[21]Roger SD, Gaillard CA, Bock AH, et al.Safety of intravenous ferric carboxymaltose versus oral iron in patients with nondialysis-dependent CKD: An analysis of the 1-year FIND-CKD trial[J].Nephrol Dial Transplant, 2017, 32(9):1530-1539
[22]Bhandari S, Kalra PA, Berkowitz M, et al.Safety and efficacy of iron isomaltoside 1000/ferric derisomaltose versus iron sucrose in patients with chronic kidney disease: The FERWON-NEPHRO randomized, open-label, comparative trial[J]. Nephrol Dial Transplant, 2020.
[23]Chen N, Hao C, Peng X, et al.Roxadustat for anemia in patients with kidney disease not receiving dialysis[J].N Engl J Med, 2019, 381(11):1001-1010
[24]Chen N, Hao C, Liu BC, et al.Roxadustat treatment for anemia in patients undergoing long-term dialysis[J].N Engl J Med, 2019, 381(11):1011-1022
[25]Jia L, Dong X, Yang J, et al.Effectiveness of hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat on renal anemia in non-dialysis-dependent chronic kidney disease: A systematic review and meta-analysis[J].Ann Transl Med, 2019, 7(23):720-
[26]Sun CC, Vaja V, Chen S, et al.A hepcidin lowering agent mobilizes iron for incorporation into red blood cells in an adenine-induced kidney disease model of anemia in rats[J].Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2013, 28(7):1733-1743
[27]Boyce M, Warrington S, Cortezi B, et al.Safety,pharmacokinetics and pharmacodynamics of the anti-hepcidin spiegelmer lexaptepid pegol in healthy subjects[J].British journal of pharmacology, 2016, 173(10):1580-1588
|
